

=> d his

(FILE 'USPAT' ENTERED AT 14:39:12 ON 12 AUG 1999)
ACTIVATE L975519/L

```

-----
L1 ( 3804)SEA FILE=USPAT ADENOVIRUS
L2 ( 183589)SEA FILE=USPAT PURIF?
L3 ( 283)SEA FILE=USPAT L1(P)L2
L4 ( 40337)SEA FILE=USPAT LYS##
L5 ( 28)SEA FILE=USPAT L3(P)L4
L6 ( 9387)SEA FILE=USPAT PERFUS?
L7 ( 266504)SEA FILE=USPAT AD#
L8 ( 268303)SEA FILE=USPAT L1 OR L7
L9 ( 197)SEA FILE=USPAT L8(P)L6
L10 ( 6)SEA FILE=USPAT L3 AND L9
L11 ( 145663)SEA FILE=USPAT CHROMATOG?
L12 ( 17)SEA FILE=USPAT L11(P)L3
L13 ( 1091)SEA FILE=USPAT L7(P)(L2)(P)(L11)
L14 ( 39)SEA FILE=USPAT L13 AND L1
L15 ( 3804)SEA FILE=USPAT ADENOVIRUS
L16 ( 39)SEA FILE=USPAT L13 AND L15
-----
L17 33 S L5
L18 6 S L10
L19 19 S L12
L20 42 S L14
SET HIGH OFF
L21 4017 S ADENOVIRUS
SET HIGH ON
L22 42 S L13 AND L21
L23 1098 S AUTOLYS?
L24 26 S L23 AND L21
L25 43 S L23(P)L8
L26 2 S L25 AND L21
=> d 117 1-5

```

1. 5,935,935, Aug. 10, 1999, Adenoviral vectors for treatment of hemophilia; Sheila Connelly, et al., 514/44; 435/320.1, 367, 370 [IMAGE AVAILABLE]

2. 5,935,840, Aug. 10, 1999, Activated recombinant adenovirus proteinases; Carl W. Anderson, et al., 435/252.3, 69.1, 252.33, 320.1; 536/23.2, 23.4 [IMAGE AVAILABLE]

5,932,210, Aug. 3, 1999, Recombinant adenoviral vector and methods of ; Richard J. Gregory, et al., 424/93.2, 93.6; 435/320.1 [IMAGE AVAILABLE]

4. 5,922,600, Jul. 13, 1999, Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1 VP2 and VP3 or sequences of that virus coding therefor; Matheus Hubertus Maria Noteborn, et al., 435/456, 235.1, 320.1, 325, 348; 536/23.1 [IMAGE AVAILABLE]

5. 5,922,576, Jul. 13, 1999, Simplified system for generating recombinant adenoviruses; Tong-Chuan He, et al., 435/91.41, 91.4, 252.3, 252.33, 320.1, 455, 471, 477, 488; 536/23.1, 23.7, 23.72 [IMAGE AVAILABLE]

=> d 119 1 2

1. 5,935,840, Aug. 10, 1999, Activated recombinant adenovirus proteinases; Carl W. Anderson, et al., 435/252.3, 69.1, 252.33, 320.1; 536/23.2, 23.4 [IMAGE AVAILABLE]

2. 5,928,944, Jul. 27, 1999, Method of adenoviral-mediated cell transfection; Prem Seth, et al., 435/375; 424/93.1, 93.2, 450; 514/44 [IMAGE AVAILABLE]

=> d 120 1-3

1. 5,935,840, Aug. 10, 1999, Activated recombinant **adenovirus** proteinases; Carl W. Anderson, et al., 435/252.3, 69.1, 252.33, 320.1; 536/23.2, 23.4 [IMAGE AVAILABLE]

2. 5,935,576, Aug. 10, 1999, Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens; Pramod K. Srivastava, 424/184.1, 193.1, 277.1; 514/2; 530/300, 350 [IMAGE AVAILABLE]

3. 5,928,944, Jul. 27, 1999, Method of adenoviral-mediated cell transfection; Prem Seth, et al., 435/375; 424/93.1, 93.2, 450; 514/44 [IMAGE AVAILABLE]

=> d L26 1 2

1. 5,851,528, Dec. 22, 1998, Methods of inhibiting complement activation; Jone-Long Ko, et al., 424/185.1, 192.1; 514/12; 530/350, 380 [IMAGE AVAILABLE]

2. 5,679,546, Oct. 21, 1997, Chimeric proteins which block complement activation; Jone-Long Ko, et al., 435/69.2, 69.7, 252.3, 320.1; 530/350, 412; 536/23.4 [IMAGE AVAILABLE]

=> d 124 1-26

1. 5,910,574, Jun. 8, 1999, Human trk receptors and neurotrophic factor inhibitors; Leonard G. Presta, et al., 530/388.22; 424/133.1, 143.1; 530/387.3, 388.1 [IMAGE AVAILABLE]

2. 5,889,166, Mar. 30, 1999, Recombinant neospore antigens and their uses; Patricia A. Conrad, et al., 536/23.1; 530/300, 350, 371 [IMAGE AVAILABLE]
3. 5,877,016, Mar. 2, 1999, Human trk receptors and neurotrophic factor inhibitors; Leonard G. Presta, et al., 435/325, 69.1, 320.1; 530/387.3, 388.22; 536/23.4 [IMAGE AVAILABLE]
4. 5,874,235, Feb. 23, 1999, Screening assays for cancer chemopreventive agents; Timothy A. Chan, et al., 435/18, 4, 7.21, 7.23, 19, 21; 436/63 [IMAGE AVAILABLE]
5. 5,858,751, Jan. 12, 1999, Compositions and methods for producing sialyltransferases; James C. Paulson, et al., 435/193, 69.1, 252.3, 320.1; 530/350; 536/23.2 [IMAGE AVAILABLE]
6. 5,851,528, Dec. 22, 1998, Methods of inhibiting complement activation; Jone-Long Ko, et al., 424/185.1, 192.1; 514/12; 530/350, 380 [IMAGE AVAILABLE]
7. 5,844,092, Dec. 1, 1998, Human TRK receptors and neurotrophic factor inhibitors; Leonard G. Presta, et al., 530/387.3; 424/133.1; 530/350 [IMAGE AVAILABLE]
8. 5,834,278, Nov. 10, 1998, Bacterial peptide methionine sulfoxide reductase an adhesion-associated protein, and antibiotic therapies based thereon; Elaine Tuomanen, et al., 435/189, 69.1, 252.3, 320.1, 885; 530/350, 412; 536/23.2, 23.7 [IMAGE AVAILABLE]
9. 5,830,849, Nov. 3, 1998, Vampire bat salivary plasminogen activators; Richard A. F. Dixon, et al., 514/2; 424/94.63; 435/69.1, 226, 252.3, 320.1, 325; 530/395; 536/23.2, 23.5 [IMAGE AVAILABLE]
10. 5,798,243, Aug. 25, 1998, Bacterial peptide methionine sulfoxide reductase, and adhesion-associated protein, and antibiotic therapies based thereon; Elaine Tuomanen, et al., 435/189, 69.1, 252.3, 320.1; 530/350; 536/23.2, 23.7 [IMAGE AVAILABLE]
11. 5,707,969, Jan. 13, 1998, Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor; Elizabeth G. Nabel, et al., 514/44; 435/6, 69.1, 320.1 [IMAGE AVAILABLE]
12. 5,707,617, Jan. 13, 1998, Bovine neospore isolates; Patricia A. Conrad, et al., 424/93.1; 435/258.1 [IMAGE AVAILABLE]
13. 5,705,379, Jan. 6, 1998, Nucleotide sequences encoding a thermostable alkaline protease; David B. Wilson, et al., 435/220, 252.3, 253.5, 320.1; 536/23.2 [IMAGE AVAILABLE]
14. 5,698,531, Dec. 16, 1997, Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor; Elizabeth G. Nabel, et al., 514/44; 435/6, 69.1, 320.1, 456, 458 [IMAGE AVAILABLE]
15. 5,679,546, Oct. 21, 1997, Chimeric proteins which block complement activation; Jone-Long Ko, et al., 435/69.2, 69.7, 252.3, 320.1; 530/350, 412; 536/23.4 [IMAGE AVAILABLE]
16. 5,569,824, Oct. 29, 1996, Transgenic mice containing a disrupted p53 gene; Lawrence A. Donehower, et al., 800/10; 424/9.1; 800/18 [IMAGE AVAILABLE]
17. 5,559,022, Sep. 24, 1996, Liver reserve cells; Brian A. Naughton, et al., 435/370; 424/93.1; 435/379 [IMAGE AVAILABLE]
18. 5,328,470, Jul. 12, 1994, Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor; Elizabeth G. Nabel, et al., 604/101, 96; 606/194 [IMAGE AVAILABLE]
19. 5,300,631, Apr. 5, 1994, Antibodies specific for either ras photo-oncogene encoded P21 proteins or ras oncogene encoded P21 proteins but not for both and method of producing same; Robert A. Weinberg, et al., 530/387.7; 435/70.21; 436/547, 548; 530/387.9, 388.24, 388.8, 388.85, 389.2, 389.7 [IMAGE AVAILABLE]
20. 5,190,756, Mar. 2, 1993, Methods and materials for expression of human plasminogen variant; Francis J. Castellino, et al., 424/94.64; 435/216, 217, 226; 514/822 [IMAGE AVAILABLE]
21. 5,087,572, Feb. 11, 1992, DNA encoding human plasminogen modified at the cleavage site; Francis J. Castellino, et al., 435/359, 217, 252.3, 320.1; 536/23.51 [IMAGE AVAILABLE]
22. 5,004,757, Apr. 2, 1991, Virucidal low toxicity compositions; Raymond M. G. Boucher, 514/694, 696, 697, 698, 705, 934 [IMAGE AVAILABLE]
23. 4,786,718, Nov. 22, 1988, Method of preparing antibodies to characterize oncogenes; Robert A. Weinberg, et al., 530/387.7; 435/7.23, 70.21; 436/547, 548; 530/389.7, 808, 809; 930/10 [IMAGE AVAILABLE]
24. 4,535,058, Aug. 13, 1985, Characterization of oncogenes and assays

based thereon; Robert A. Weinberg, et al., 435/6, 15, 18, 91.53; 436/27, 63, 64, 94, 504, 515, 813; 536/23.5, 24.1; 930/10 [IMAGE AVAILABLE]

25. 4,124,702, Nov. 7, 1978, Polynucleotides active as inducers of interferon production in living animal cells; George P. Lampson, et al., 514/44; 435/70.3; 514/43, 889; 536/23.1, 23.52, 23.72, 25.5 [IMAGE AVAILABLE]

26. 4,070,453, Jan. 24, 1978, Diploid porcine embryonic cell strains, cultures produced therefrom, and use of said cultures for production of vaccines; Dale Emil Bordt, et al., 435/325; 424/204.1, 211.1, 215.1, 216.1, 218.1, 223.1, 224.1, 233.1, 815; 435/213, 219, 235.1, 378, 392 [IMAGE AVAILABLE]

=> save all 1975519/1

'L975519/L' IN USE

REPLACE OLD DEFINITION? Y/(N):y

L# LIST 'L1-L26' HAS BEEN SAVED AS 'L975519/L'

95% OF LIMIT FOR SAVED L# LISTS REACHED

=> log hold

SESSION WILL BE HELD FOR 30 MINUTES

U.S. Patent & Trademark Office SESSION SUSPENDED AT 14:54:22 ON 12 AUG 199

9

Connection closed by remote host